Join
Live feed
·
INSIDERFilingvia Quantisnow
Axsome Therapeutics Inc. logo

Director Coleman Mark sold $4,019,470 worth of shares (17,537 units at $229.20) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 29,603 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AXSM· Axsome Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AXSM (Axsome Therapeutics Inc.) and more on Quantisnow.